News Release: Foundation for Women’s Cancer Applauds FDA Decision to Include HPV Testing as Part of Primary Screening for Cervical Cancer: A Step Forward in Eliminating Cervical Cancer

CHICAGO, March 13, 2014 – The Foundation for Women’s Cancer applauds the decision made by an expert panel at the FDA yesterday to include HPV testing as part of first-line primary screening for cervical cancer. The combination of the HPV test and the Pap test can reassure women about their screening results, and is especially important for women over 30 who may be able to extend screening intervals based upon these results.

“This decision represents the next step in eliminating cervical cancer through this more accurate screening combination,” said Dr. Mark Einstein on behalf of the Foundation for Women’s Cancer. “It is especially important in the detection of less common but very aggressive adenocarcinomas, plus it affords better clinical management. It offers women and their healthcare providers another primary cervical cancer screening option.”

Each year more than 12,350 cases of invasive cervical cancer will be diagnosed in the U.S. and more than 4,000 women will die from the preventable cancer. The introduction of the first cervical cancer vaccine in 2006 for primary prevention was a milestone in the eventual elimination of cervical cancer. The Foundation for Women’s Cancer urges all young people to be vaccinated and all women to undergo regular primary screening.

About the Foundation for Women’s Cancer

The Foundation for Women’s Cancer, in concert with the Society of Gynecologic Oncology, is dedicated to expanding public awareness, education, research and training to improve the prevention, early detection and optimal treatment of gynecologic cancers. A national organization dedicated to the eradication of all reproductive cancers, the Foundation has provided more than $5.4 million in research funding since 1995, earning recognition from Worth Magazine as one of the nation’s 100 best charities. For more information, visit foundationforwomenscancer.org.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.